The First-Ever Clinical Trial Using Tocotrienols with Ovarian Cancer Patients, Increased their Survival by Seventy Percent in Refractory Ovarian Cancer

February 7, 2019 3:00 pm

The following article is provided by The Clearity Foundation to support women with ovarian cancer and their families. Learn more about The Clearity Foundation and the services we provide directly to women as they make treatment decisions and navigate emotional impacts of their diagnosis.


A recent study conducted at Denmark’s Vejle Hospital, published in Pharmacological Research, provides evidence of delta-tocotrienol’s benefits for cancer patients. Results of the open-label trial suggest that American River Nutrition-manufactured delta-tocotrienol in combination with bevacizumab had additive effects in chemotherapy refractory ovarian cancer, possibly conferred by the anti-angiogenic activity of both compounds. This is the first-ever clinical trial using tocotrienols in ovarian cancer patients.

In the study of 23 advanced-stage ovarian cancer patients, tocotrienol was administered at a dosage of 300mg three times a day, with bevacizumab given to patients at 10mg/kg intravenously every three weeks. Patient disease stabilization was high at 70%, with increased survival, which approximately doubled.

“What is so exciting about this study, is that it supports the growing body of evidence that tocotrienols can be life changing,” comments Designs for Health Co-founder and Board President Jonathan Lizotte. “I applaud the Danish government and Dr. Jakobsen and his group for their open-minded and novel approach in using a vitamin in conjunction with a standard therapy. It’s this forward thinking that will inevitably result in major breakthroughs for the treatment and prevention of cancer and other life-threatening diseases.”

Ovarian cancer is the 5th most common cause of cancer death in women in the US. According to the American Cancer Society, approximately 22,240 women in the US received a new ovarian cancer diagnosis, while approximately 14,070 people died of the disease in 2018. Since ovarian cancer is usually not diagnosed until it is more advanced, the 5-year survival rate is only 47%. Patients with advanced-stage ovarian cancer often have a recurrence of the disease after primary treatment, and despite second and third line treatments, these patients eventually become chemotherapy-resistant with few therapeutic options. The goal at this stage is to improve the quality and duration of life with as few side effects as possible. The study treatment was shown to have low toxicity, with only three patients discontinuing their medications due to well-known side effects of bevacizumab therapy. Further, quality of life was stable.

Commenting on the research, which used their delta-tocotrienol (Delta Gold®), Dr. Barrie Tan, President of American River Nutrition said that “ovarian cancer is one of the most deadly cancers in women, and as researchers, we have to be open to new thinking if we are to make advances in finding alternative treatments.” Tan continued, “I have spent over twenty years studying tocotrienols, specifically from the annatto plant, and their positive effects on multiple health issues, but this study is the first of its kind to shed new light onto the way tocotrienols can be used to enhance and prolong life for ovarian cancer patients.

Source: Pharmacological Research
doi: 10.1016/j.phrs.2019.01.017
Delta tocotrienol in recurrent ovarian cancer. A phase II trial.
Authors: Thomsen, C.B., Andersen, R.F., Steffensen, K.D., Adimi, P., Jakobsen, A.

This article was published by

Leave a Reply

Your email address will not be published. Required fields are marked *

Return to Blog Home Return to Clearity Foundation Home